Barely Significant
← all phrases

“a statistical trend”

2,799 sentences · 2,799 papers · 4,784 search hits before verification · confirmed specimen

Sighted at

p=0.09

Listed by Hankins (2013) · Otte et al. (2022)

In the literature

Thirteen of 17 studies reported that low ERCC1 correlated with better clinical outcome (total n = 1815), 77 – 85 , 87 , 91 , 92 or had a statistical trend towards better outcome (total n = 218). 38 Two studies showed no correlation between ERCC1 level and outcome (n = 218), 89 , 90 while two studies showed a significantly worse outcome (total n = 269) 27 , 88 in patients with tumors expressing low levels of ERCC1.
ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer.
Pharmgenomics Pers Med · 2011 · PMC3513219
Those who stated that they did not consider collective activities important presented worse adherence (p < 0.001) Some variables indicated a statistical trend to difference between the groups, that was not significant, but indicated better adherence among participants with longer time since onset of diagnosis and treatment (p = 0.064), psychotic underlying diagnosis (p = 0.093), and higher scores in the FAST Interpersonal Relations domain (p = 0.077).
However, when assessing the LN metastases count in stage IIIb and a minimum of five retrieved LNs, there was a statistical trend for shorter RFS and distant recurrence in patients with more than five LN metastases (< 5 LN metastases: median RFS not reached vs. ≥ 5 LN metastases: 86.8 months 95% CI = 46–127.6; log‐rank, p = .061) (see Supporting information, Figure S2B ), but no evident difference for locoregional recurrence (< 5 LN metastases: median RFS not reached vs. ≥ 5 LN metastases: 73.67 months 95% CI = 36.1–111.2; log‐rank, p = .603) (see Supporting information, Figure S2A ).
Results Monocyte cytokine responses to CHCs While examining the ability of CHCs to stimulate production of pro-inflammatory cytokines by unprimed human monocytes, we observed significant secretion of IL-1β, TNF-α, IL-6 ( Fig 1A–1C ), and a statistical trend towards IL-8 secretion ( Fig 1E ).
Phase II trials in melanoma demonstrate dose-dependent responsiveness In a Phase II dose-finding study of ipilimumab in metastatic melanoma, responses were noted in a dose-dependent fashion when ipilimumab was dosed at 0.3 mg/kg, 3 mg/kg, and 10 mg/kg every 3 weeks for four doses and analyzed using a statistical trend test. 26 Ipilimumab was noted to be clinically active at doses of 3 mg/kg and higher.